Aprotinin enhances the endogenous release of interleukin-10 after cardiac operations

Gary E. Hill, Robert P. Diego, Alfred H. Stammers, Suzanne M. Huffman, Roman Pohorecki

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

Background. Cardiopulmonary bypass (CPB) is characterized by the systemic release of proinflammatory cytokines, such as tumor necrosis factor- α and the interleukins 1 and 6, as well as endogenous antiinflammatory cytokines, including interleukin-10 (IL-10). Glucocorticoids reduce tumor necrosis factor-α plasma concentrations while enhancing IL-10 plasma concentrations after CPB. Aprotinin, a serine protease inhibitor used primarily to reduce blood loss after CPB, reduces CPB-induced proinflammatory cytokine tumor necrosis factor-α release similarly to glucocorticoids. This study evaluates the effect of full-dose aprotinin on the plasma concentrations of IL-10 after CPB. Methods. Twenty adults were randomized into a control (group C, n = 10) and a full-dose aprotinin-treated group (group A, n = 10). Plasma levels of IL-10 were measured by enzyme-linked immunosorbent assay technique at baseline (before anesthetic induction), and at 1 and 24 hours after CPB termination. Results. A significant (p < 0.05) increase of IL-10 occurred in both groups at 1 and 24 hours after termination of CPB when compared with the same group at baseline. In group A, the increase in IL-10 was significantly greater than in group C (p < 0.05) at 24 hours after CPB. Conclusions. These results demonstrate an endogenous antiinflammatory response generated after CPB, characterized by IL-10 release, that is enhanced by aprotinin therapy. This study demonstrates a unique antiinflammatory activity of aprotinin that may be of clinical significance.

Original languageEnglish (US)
Pages (from-to)66-69
Number of pages4
JournalAnnals of Thoracic Surgery
Volume65
Issue number1
DOIs
StatePublished - Jan 1998

Fingerprint

Aprotinin
Cardiopulmonary Bypass
Interleukin-10
Anti-Inflammatory Agents
Tumor Necrosis Factor-alpha
Cytokines
Glucocorticoids
Immunosorbent Techniques
Serine Proteinase Inhibitors
Interleukin-1
Anesthetics
Interleukin-6
Enzyme-Linked Immunosorbent Assay
Control Groups

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Surgery

Cite this

Aprotinin enhances the endogenous release of interleukin-10 after cardiac operations. / Hill, Gary E.; Diego, Robert P.; Stammers, Alfred H.; Huffman, Suzanne M.; Pohorecki, Roman.

In: Annals of Thoracic Surgery, Vol. 65, No. 1, 01.1998, p. 66-69.

Research output: Contribution to journalArticle

Hill, Gary E. ; Diego, Robert P. ; Stammers, Alfred H. ; Huffman, Suzanne M. ; Pohorecki, Roman. / Aprotinin enhances the endogenous release of interleukin-10 after cardiac operations. In: Annals of Thoracic Surgery. 1998 ; Vol. 65, No. 1. pp. 66-69.
@article{b66e6d2c59cc4d93b30e1d64d62fcddb,
title = "Aprotinin enhances the endogenous release of interleukin-10 after cardiac operations",
abstract = "Background. Cardiopulmonary bypass (CPB) is characterized by the systemic release of proinflammatory cytokines, such as tumor necrosis factor- α and the interleukins 1 and 6, as well as endogenous antiinflammatory cytokines, including interleukin-10 (IL-10). Glucocorticoids reduce tumor necrosis factor-α plasma concentrations while enhancing IL-10 plasma concentrations after CPB. Aprotinin, a serine protease inhibitor used primarily to reduce blood loss after CPB, reduces CPB-induced proinflammatory cytokine tumor necrosis factor-α release similarly to glucocorticoids. This study evaluates the effect of full-dose aprotinin on the plasma concentrations of IL-10 after CPB. Methods. Twenty adults were randomized into a control (group C, n = 10) and a full-dose aprotinin-treated group (group A, n = 10). Plasma levels of IL-10 were measured by enzyme-linked immunosorbent assay technique at baseline (before anesthetic induction), and at 1 and 24 hours after CPB termination. Results. A significant (p < 0.05) increase of IL-10 occurred in both groups at 1 and 24 hours after termination of CPB when compared with the same group at baseline. In group A, the increase in IL-10 was significantly greater than in group C (p < 0.05) at 24 hours after CPB. Conclusions. These results demonstrate an endogenous antiinflammatory response generated after CPB, characterized by IL-10 release, that is enhanced by aprotinin therapy. This study demonstrates a unique antiinflammatory activity of aprotinin that may be of clinical significance.",
author = "Hill, {Gary E.} and Diego, {Robert P.} and Stammers, {Alfred H.} and Huffman, {Suzanne M.} and Roman Pohorecki",
year = "1998",
month = "1",
doi = "10.1016/S0003-4975(97)01037-0",
language = "English (US)",
volume = "65",
pages = "66--69",
journal = "Annals of Thoracic Surgery",
issn = "0003-4975",
publisher = "Elsevier USA",
number = "1",

}

TY - JOUR

T1 - Aprotinin enhances the endogenous release of interleukin-10 after cardiac operations

AU - Hill, Gary E.

AU - Diego, Robert P.

AU - Stammers, Alfred H.

AU - Huffman, Suzanne M.

AU - Pohorecki, Roman

PY - 1998/1

Y1 - 1998/1

N2 - Background. Cardiopulmonary bypass (CPB) is characterized by the systemic release of proinflammatory cytokines, such as tumor necrosis factor- α and the interleukins 1 and 6, as well as endogenous antiinflammatory cytokines, including interleukin-10 (IL-10). Glucocorticoids reduce tumor necrosis factor-α plasma concentrations while enhancing IL-10 plasma concentrations after CPB. Aprotinin, a serine protease inhibitor used primarily to reduce blood loss after CPB, reduces CPB-induced proinflammatory cytokine tumor necrosis factor-α release similarly to glucocorticoids. This study evaluates the effect of full-dose aprotinin on the plasma concentrations of IL-10 after CPB. Methods. Twenty adults were randomized into a control (group C, n = 10) and a full-dose aprotinin-treated group (group A, n = 10). Plasma levels of IL-10 were measured by enzyme-linked immunosorbent assay technique at baseline (before anesthetic induction), and at 1 and 24 hours after CPB termination. Results. A significant (p < 0.05) increase of IL-10 occurred in both groups at 1 and 24 hours after termination of CPB when compared with the same group at baseline. In group A, the increase in IL-10 was significantly greater than in group C (p < 0.05) at 24 hours after CPB. Conclusions. These results demonstrate an endogenous antiinflammatory response generated after CPB, characterized by IL-10 release, that is enhanced by aprotinin therapy. This study demonstrates a unique antiinflammatory activity of aprotinin that may be of clinical significance.

AB - Background. Cardiopulmonary bypass (CPB) is characterized by the systemic release of proinflammatory cytokines, such as tumor necrosis factor- α and the interleukins 1 and 6, as well as endogenous antiinflammatory cytokines, including interleukin-10 (IL-10). Glucocorticoids reduce tumor necrosis factor-α plasma concentrations while enhancing IL-10 plasma concentrations after CPB. Aprotinin, a serine protease inhibitor used primarily to reduce blood loss after CPB, reduces CPB-induced proinflammatory cytokine tumor necrosis factor-α release similarly to glucocorticoids. This study evaluates the effect of full-dose aprotinin on the plasma concentrations of IL-10 after CPB. Methods. Twenty adults were randomized into a control (group C, n = 10) and a full-dose aprotinin-treated group (group A, n = 10). Plasma levels of IL-10 were measured by enzyme-linked immunosorbent assay technique at baseline (before anesthetic induction), and at 1 and 24 hours after CPB termination. Results. A significant (p < 0.05) increase of IL-10 occurred in both groups at 1 and 24 hours after termination of CPB when compared with the same group at baseline. In group A, the increase in IL-10 was significantly greater than in group C (p < 0.05) at 24 hours after CPB. Conclusions. These results demonstrate an endogenous antiinflammatory response generated after CPB, characterized by IL-10 release, that is enhanced by aprotinin therapy. This study demonstrates a unique antiinflammatory activity of aprotinin that may be of clinical significance.

UR - http://www.scopus.com/inward/record.url?scp=0031881751&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031881751&partnerID=8YFLogxK

U2 - 10.1016/S0003-4975(97)01037-0

DO - 10.1016/S0003-4975(97)01037-0

M3 - Article

C2 - 9456097

AN - SCOPUS:0031881751

VL - 65

SP - 66

EP - 69

JO - Annals of Thoracic Surgery

JF - Annals of Thoracic Surgery

SN - 0003-4975

IS - 1

ER -